Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

Next Previous
Search
Trial Profile

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary) ; Cabozantinib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PIVOT-09
  • Sponsors Nektar Therapeutics

    • Most Recent Events

    • 14 Nov 2022 Status changed from active, no longer recruiting to discontinued.
    • 13 Sep 2022 Results reporting safety and efficacy data at a median follow-up of 15.5 months presented at the 47th European Society for Medical Oncology Congress
    • 05 Sep 2022 According to a Bristol-Myers Squibb media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top